Characteristics of the patients
Patient No. . | Diagnosis . | Age, y, at AHSCT . | Sex . | HLA matches, n/6 . | Before treatment . | Conditioning regimen . | Type of AHSCT . | GvHD-prophytaxis treatment . | sjTREC pre-AHSCT (copies/mL blood) . |
|---|---|---|---|---|---|---|---|---|---|
| Group 1 with | |||||||||
| sjTREC ≥ 1200 | |||||||||
| 1 | Aplastic anemia | 3 | M | 3/6 | Str/IVIG/CSA/ATG | TLI/Cy/Fl/OKT3/ATG | CD34+PBSC | — | 128 019 |
| 2 | Aplastic anemia | 9 | M | 3/6 | Str/IVIG/CSA/ATG | TLI/Cy/Fl/OKT3/ATG | CD34+PBSC | — | 6 370 |
| 3 | Aplastic anemia | 11 | M | 3/6 | Str/IVIG/CSA/ATG | TLI/Cy/Fl/OKT3/ATG | CD34+PBSC | 216 513 | |
| 4 | Hurler syndrome | 13 | M | 3/6 | Bu/Cy/MUDSCT | TLI/Mel/Fl/OKT3/ATG | CD34+PBSC | — | 11 961 |
| 5 | AML | 14 | M | 6/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 20 693 |
| 6 | AML | 8 | F | 3/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 13 985 |
| 7 | AML | 16 | F | 6/6 | sAML | TBI/Cy/Th/ATG | BM | CSA/MTX | 4 655 |
| 8 | AML | 7 | F | 6/6 | sAML | TBI/Cy/Th/ATG | BM | CSA/MTX | 2 893 |
| 9 | AML | 17 | M | 3/6 | sAML, sRMS, rRMS | Fl/Mel/Th/OKT3 | CD3– PBSC | MMF | 1 693 |
| 10 | ALL | 7 | M | 6/6 | hrALL | TBI/Cy/Th/ATG | CD34+BMSC | CSA | 40 792 |
| 11 | bALL | 5 | F | 3/6 | sALL, sAML, FLAG | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 5 478 |
| 12 | bALL | 8 | F | 6/6 | sALL, sAML | TBI/Cy/Th/ATG | BM | CSA | 7 704 |
| 13 | ALL | 5 | F | 4/6 | sALL | Cy/Th/ATG | CD34+PBSC | — | 3 687 |
| 14 | ALL | 12 | M | 6/6 | sALL, rALL, FLAG | TBI/Cy/Th/ATG | BM | CSA/MTX | 1 620 |
| 15 | CML | 17 | F | 3/6 | GL, MY | Fl/Mel/Th/OKT3 | CD3– PBSC | MMF | 29 260 |
| 16 | JMML | 2 | M | 6/6 | sAML, RA | TBI/Cy/Th/ATG | BM | CSA/MTX | 10 228 |
| Mean ± SE | 9.6 ± 1.2 | 31 597 ± 14 558 | |||||||
| Group 2 with | |||||||||
| sjTREC < 1200 | |||||||||
| 1 | AML | 14 | F | 3/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 312 |
| 2 | AML | 19 | F | 3/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 191 |
| 3 | AML | 18 | M | 6/6 | sAML | TBI/Cy/Th/ATG | CD34+BMSC | CSA | 54 |
| 4 | AML | 17 | M | 3/6 | sAML | TBI/Cy/Th/ATG | BM | CSA/MTX | 281 |
| 5 | ALL | 9 | M | 3/6 | sALL | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 17 |
| 6 | ALL | 11 | M | 6/6 | sALL | TBI/Cy/Th/ATG | CD34+BMSC | CSA | 359 |
| 7 | ALL | 14 | F | 3/6 | sAML | Et/Th | CD34+PMSC | CSA/MMF | 6 |
| 8 | ALL | 18 | M | 6/6 | sALL | TBI/Cy/Th/ATG | BM | CSA/MTX | 0 |
| 9 | ALL | 18 | M | 3/6 | sALL | Fl/Mel/Th/OKT3 | CD3– PBSC | MMF | 22 |
| 10 | Lymphoma | 17 | M | 3/6 | sLCL | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 398 |
| Mean ± SE | 15.5 ± 1 | 164 ± 51 | |||||||
| Total mean ± SE | 11.8 ± 1 | 19 507 ± 9 360 |
Patient No. . | Diagnosis . | Age, y, at AHSCT . | Sex . | HLA matches, n/6 . | Before treatment . | Conditioning regimen . | Type of AHSCT . | GvHD-prophytaxis treatment . | sjTREC pre-AHSCT (copies/mL blood) . |
|---|---|---|---|---|---|---|---|---|---|
| Group 1 with | |||||||||
| sjTREC ≥ 1200 | |||||||||
| 1 | Aplastic anemia | 3 | M | 3/6 | Str/IVIG/CSA/ATG | TLI/Cy/Fl/OKT3/ATG | CD34+PBSC | — | 128 019 |
| 2 | Aplastic anemia | 9 | M | 3/6 | Str/IVIG/CSA/ATG | TLI/Cy/Fl/OKT3/ATG | CD34+PBSC | — | 6 370 |
| 3 | Aplastic anemia | 11 | M | 3/6 | Str/IVIG/CSA/ATG | TLI/Cy/Fl/OKT3/ATG | CD34+PBSC | 216 513 | |
| 4 | Hurler syndrome | 13 | M | 3/6 | Bu/Cy/MUDSCT | TLI/Mel/Fl/OKT3/ATG | CD34+PBSC | — | 11 961 |
| 5 | AML | 14 | M | 6/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 20 693 |
| 6 | AML | 8 | F | 3/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 13 985 |
| 7 | AML | 16 | F | 6/6 | sAML | TBI/Cy/Th/ATG | BM | CSA/MTX | 4 655 |
| 8 | AML | 7 | F | 6/6 | sAML | TBI/Cy/Th/ATG | BM | CSA/MTX | 2 893 |
| 9 | AML | 17 | M | 3/6 | sAML, sRMS, rRMS | Fl/Mel/Th/OKT3 | CD3– PBSC | MMF | 1 693 |
| 10 | ALL | 7 | M | 6/6 | hrALL | TBI/Cy/Th/ATG | CD34+BMSC | CSA | 40 792 |
| 11 | bALL | 5 | F | 3/6 | sALL, sAML, FLAG | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 5 478 |
| 12 | bALL | 8 | F | 6/6 | sALL, sAML | TBI/Cy/Th/ATG | BM | CSA | 7 704 |
| 13 | ALL | 5 | F | 4/6 | sALL | Cy/Th/ATG | CD34+PBSC | — | 3 687 |
| 14 | ALL | 12 | M | 6/6 | sALL, rALL, FLAG | TBI/Cy/Th/ATG | BM | CSA/MTX | 1 620 |
| 15 | CML | 17 | F | 3/6 | GL, MY | Fl/Mel/Th/OKT3 | CD3– PBSC | MMF | 29 260 |
| 16 | JMML | 2 | M | 6/6 | sAML, RA | TBI/Cy/Th/ATG | BM | CSA/MTX | 10 228 |
| Mean ± SE | 9.6 ± 1.2 | 31 597 ± 14 558 | |||||||
| Group 2 with | |||||||||
| sjTREC < 1200 | |||||||||
| 1 | AML | 14 | F | 3/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 312 |
| 2 | AML | 19 | F | 3/6 | sAML | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 191 |
| 3 | AML | 18 | M | 6/6 | sAML | TBI/Cy/Th/ATG | CD34+BMSC | CSA | 54 |
| 4 | AML | 17 | M | 3/6 | sAML | TBI/Cy/Th/ATG | BM | CSA/MTX | 281 |
| 5 | ALL | 9 | M | 3/6 | sALL | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 17 |
| 6 | ALL | 11 | M | 6/6 | sALL | TBI/Cy/Th/ATG | CD34+BMSC | CSA | 359 |
| 7 | ALL | 14 | F | 3/6 | sAML | Et/Th | CD34+PMSC | CSA/MMF | 6 |
| 8 | ALL | 18 | M | 6/6 | sALL | TBI/Cy/Th/ATG | BM | CSA/MTX | 0 |
| 9 | ALL | 18 | M | 3/6 | sALL | Fl/Mel/Th/OKT3 | CD3– PBSC | MMF | 22 |
| 10 | Lymphoma | 17 | M | 3/6 | sLCL | TBI/Cy/Th/OKT3/ATG | CD34+PBSC | — | 398 |
| Mean ± SE | 15.5 ± 1 | 164 ± 51 | |||||||
| Total mean ± SE | 11.8 ± 1 | 19 507 ± 9 360 |
Str indicates steroid; IVIG, intravenous immunoglobulin; CSA, cyclosporine; ATG, antithymocyte globulin; TLI, total lymphoid irradiation; Cy, cyclophosphamide; Fl, fludarabine; OKT3, anti-CD3 antibody muromonab; ATG, antithymocyte globulin; CD34+ PBSC, CD34+ selected peripheral blood stem cells; Bu, busulfan; MUDSCT, matched unrelated donor stem cell transplantation; Mel, melphalan; AML, acute myelocytic leukemia; sAML, standard AML therapy; TBI, total body irradiation; Th, thiotepa; BM, unmanipulated bone marrow; MTX, methotrexate; sRMS, standard rhabdomyosarcoma therapy; rRMS, relapsed rhabdomyosarcoma therapy; CD3– PBSC, CD3-depleted peripheral blood stem cells; MMF, mycophenolate mofetil; ALL, acute lymphoblastic leukemia; hrALL, high-risk ALL therapy; CD34+ BMSC, CD34+ selected bone marrow stem cells and repleted with 5 × 105 CD3– T cells/kg; bALL, biphenotypic ALL; sALL, standard ALL therapy; FLAG, fludarabine and AraC with granulocyte colony-stimulating factor (GCSF); rALL, relapsed ALL therapy; CML, chronic myelocytic leukemia; GL, imatinib mesylate (Gleevec); MY, gemtuzumab ozogamicin (Mylotarg); JMML, juvenile myelomonocytic leukemia; RA, retinoic acid; Et, etoposide; sLCL, standard chemotherapy for large cell lymphoma;—, not treated.